Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Sinclair
Harvard Medical School, Department: Genetics
Should you be removed from our database? Contact us at [email protected]. Read more below.
OvaScience
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Ovascience is focused on exploring the effect NMN has on mitochondrial function. Dr. Sinclair may test the effect of NMN on mice and oocytes in his research. As such, Dr. Sinclair's financial interest in OvaScience could directly and significantly affect the design, conduct or reporting of the research.
SIRT1 as a regulator of health and lifespan of mammals
This study is aimed at understanding why highly metabolic organs lose their function over time. The SIRT1 gene is conserved from yeast to humans and plays important roles in protecting organs from the effects of aging. Our preliminary findings indicate that decline in SIRT1 activity during aging leads to a breakdown in communication between the nuclear and mitochondrial genomes, leading to mitochondrial dysfunction. This project will investigate how this process occurs and what deleterious effects it has on energy metabolism, physical strength, endurance, and memory. Then we test if the effects are reversible by raising SIRT1 activity in elderly mice. Finally we investigate novel factors that allw mitochondria to coordinate their activities, both within the cell and with other organs. These findings may lead to practical strategies for treating rare mitochondrial diseases and common age-related diseases such as Type II diabetes, heart failure, muscle wasting, and neurodegeneration.
Filed on October 23, 2014.
Tell us what you know about David Sinclair's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
David Sinclair filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Sinclair | Harvard Medical School | Conflict of Interest | Cohbar, Inc. | >$600,000 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences | $250,000 - $299,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | GlaxoSmithKline | $40,000 - $59,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Senolytic Therapeutics | $40,000 - $59,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Ovscience | $40,000 - $59,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Ovscience | $40,000 - $59,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | OvaScience | $10,000 - $19,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | OvaScience | $5,000 - $9,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | GlaxoSmithKline | $5,000 - $9,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences (parent company) and Jumpstart Fertility (wholly owned subsidiary operated by Life) | $0 - $4,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | EdenRoc Sciences (parent company of Metro International Biotech and Liberty Biosecurity) | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Iduna Therapeutics | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Jupiter Orphan Therapeutics | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Liberty Biosecurity (wholly owned and operated subsidiary of EdenRoc Sciences) and EdenRoc Sciences | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Liberty Biosecurity (wholly owned and operated subsidiary of EdenRoc Sciences) and EdenRoc Sciences | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | EdenRoc Science | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences (parent company) and Jumpstart Fertility (wholly owned subsidiary operated by Life) | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Spotlight Biosciences Inc. | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Jumpstart Fertility (a subsidiary of Life Biosciences) | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Senolytic Therapeutics | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Metrobiotech East, LLC | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | MetroBiotech Midatlantic, LLC | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences (parent company) and Jupiter Orphan (wholly owned subsidiary operated by Life) | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.